Get the Stockscreener App
47.47
0.23%
-0.11
After Hours:
47.30
-0.17
-0.36%
Protagonist Therapeutics Inc stock is traded at $47.47, with a volume of 789.66K.
It is down -0.23% in the last 24 hours and up +4.06% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$47.58
Open:
$47.37
24h Volume:
789.66K
Relative Volume:
0.68
Market Cap:
$2.94B
Revenue:
$45.48M
Net Income/Loss:
$169.95M
P/E Ratio:
18.12
EPS:
2.62
Net Cash Flow:
$230.85M
1W Performance:
+3.96%
1M Performance:
+4.06%
6M Performance:
+8.38%
1Y Performance:
+71.31%
1-Day Range:
$46.16
$47.74
1-Week Range:
$45.28
$47.74
52-Week Range:
$27.60
$60.60
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
47.47 | 2.83B | 45.48M | 169.95M | 230.85M | 2.62 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera - Quantisnow
Protagonist Therapeutics (NASDAQ:PTGX) Downgraded to Sell Rating by Wall Street Zen - Defense World
Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome - MSN
D. E. Shaw & Co. Inc. Sells 21,121 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Bank of America Corp DE Has $5.21 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics’ SWOT analysis: stock poised for growth amid clinical advancements - Investing.com India
Protagonist Therapeutics’ SWOT analysis: stock poised for growth amid clinical advancements By Investing.com - Investing.com South Africa
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Position Reduced by Ameriprise Financial Inc. - Defense World
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 - The Arizona Republic
BNP Paribas Financial Markets Has $751,000 Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 | PTGX Stock News - GuruFocus
Exclusive: Protagonist Therapeutics CEO Reveals Company Strategy at Major Jefferies Healthcare Conference - Stock Titan
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of “Buy” from Analysts - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Given “Buy” Rating at HC Wainwright - Defense World
PTGX: HC Wainwright & Co. Reiterates Buy Rating with $80 Target | PTGX Stock News - GuruFocus
Protagonist Therapeutics Insiders Sold US$5.1m Of Shares Suggesting Hesitancy - simplywall.st
HC Wainwright Brokers Reduce Earnings Estimates for PTGX - Defense World
Q2 Earnings Estimate for PTGX Issued By HC Wainwright - Defense World
Wedbush Equities Analysts Boost Earnings Estimates for PTGX - Defense World
Protagonist Therapeutics (PTGX) Reveals Promising Phase 3 Trial Results | PTGX Stock News - GuruFocus
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study - Benzinga
Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Johnson & Johnson, Protagonist Therapeutics Say Psoriasis Drug Cleared Skin in Late-Stage Study - marketscreener.com
J&J posts late-stage data for plaque psoriasis drug (JNJ:NYSE) - Seeking Alpha
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting - Stock Titan
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 - ACCESS Newswire
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update - ACCESS Newswire
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - Yahoo Finance
Protagonist Therapeutics: Strategic Advances and Promising Pipeline Drive Buy Rating - TipRanks
Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience - insights.citeline.com
Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus
Protagonist Therapeutics: Q1 Earnings Snapshot - CTPost
Protagonist Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Protagonist (PTGX) Reports Q1 Revenue Below Expectations While A - GuruFocus
Protagonist (PTGX) Reports Q1 Revenue Below Expectations While Advancing Drug Pipeline | PTGX Stock News - GuruFocus
Protagonist Therapeutics, Inc SEC 10-Q Report - TradingView
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update | PTGX Stock News - GuruFocus
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update - ACCESS Newswire
Protagonist Hits Major Clinical Win: Phase 3 Trial Success Sets Stage for Two FDA Filings in 2025 - Stock Titan
Envestnet Asset Management Inc. Lowers Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference - ACCESS Newswire
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Mariner LLC - Defense World
Wells Fargo & Company MN Raises Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Brokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $65.44 - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Daily Progress: Protagonist Therapeutics Inc (PTGX) Drop -2.84, Closing at 44.85 - DWinneX
Bank of Montreal Can Increases Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Protagonist Therapeutics Inc Stock (PTGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ali Asif | Chief Financial Officer |
Apr 22 '25 |
Sale |
46.00 |
1,756 |
80,776 |
61,065 |
| Waddill William D. | Director |
Mar 17 '25 |
Sale |
54.25 |
4,000 |
217,000 |
13,130 |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):